Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Aug;58(2):189–190. doi: 10.1038/bjc.1988.190

The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).

B M Cantwell 1, A L Harris 1
PMCID: PMC2246772  PMID: 3166908

Full text

PDF
189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bassendine M. F., Curtin N. J., Loose H., Harris A. L., James O. F. Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study. J Hepatol. 1987 Jun;4(3):349–356. doi: 10.1016/s0168-8278(87)80545-7. [DOI] [PubMed] [Google Scholar]
  2. Calvert A. H., Alison D. L., Harland S. J., Robinson B. A., Jackman A. L., Jones T. R., Newell D. R., Siddik Z. H., Wiltshaw E., McElwain T. J. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol. 1986 Aug;4(8):1245–1252. doi: 10.1200/JCO.1986.4.8.1245. [DOI] [PubMed] [Google Scholar]
  3. Calvert A. H., Newell D. R., Jackman A. L., Gumbrell L. A., Sikora E., Grzelakowska-Sztabert B., Bishop J. A., Judson I. R., Harland S. J., Harrap K. R. Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717). NCI Monogr. 1987;(5):213–218. [PubMed] [Google Scholar]
  4. Cantwell B. M., Macaulay V., Harris A. L., Kaye S. B., Smith I. E., Milsted R. A., Calvert A. H. Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer. Eur J Cancer Clin Oncol. 1988 Apr;24(4):733–736. doi: 10.1016/0277-5379(88)90307-0. [DOI] [PubMed] [Google Scholar]
  5. Diddens H., Niethammer D., Jackson R. C. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res. 1983 Nov;43(11):5286–5292. [PubMed] [Google Scholar]
  6. Grem J. L., Hoth D. F., Hamilton J. M., King S. A., Leyland-Jones B. Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep. 1987 Dec;71(12):1249–1264. [PubMed] [Google Scholar]
  7. Harding M. J., Cantwell B. M., Milstead R. A., Harris A. L., Kaye S. B. Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer. Br J Cancer. 1988 Jun;57(6):628–629. doi: 10.1038/bjc.1988.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Houghton J. A., Maroda S. J., Jr, Phillips J. O., Houghton P. J. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res. 1981 Jan;41(1):144–149. [PubMed] [Google Scholar]
  9. Jones T. R., Calvert A. H., Jackman A. L., Brown S. J., Jones M., Harrap K. R. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer. 1981 Jan;17(1):11–19. doi: 10.1016/0014-2964(81)90206-1. [DOI] [PubMed] [Google Scholar]
  10. Moertel C. G. Chemotherapy of gastrointestinal cancer. N Engl J Med. 1978 Nov 9;299(19):1049–1052. doi: 10.1056/NEJM197811092991906. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES